

National Center  
7272 Greenville Avenue  
Dallas, Texas 75231-4596  
Tel 214 373 6300  
<http://www.americanheart.org>

September 24, 1997

Mr. Joel I. Klein  
Asst. U.S. Attorney General  
Department of Justice, Antitrust Division  
950 Pennsylvania Avenue  
Room 3109  
Washington, D.C. 20530

Re: Business Review Request of the American Heart Association  
Pharmaceutical Round Table

Dear Mr. Klein:

By letter dated February 1, 1988, the American Heart Association submitted to the Antitrust Division of the Department of Justice a business review letter with regard to the proposed Pharmaceutical Round Table ("PRT"), of which the American Heart Association is a founding member. A favorable response was made by your division to this request by letter dated April 28, 1989. Copies of these two letters as well as a May 3, 1989 Department of Justice Release are attached hereto for your reference.

The purpose of this letter is to make a further business review request regarding proposed changes to the previously reviewed PRT in accordance with 28 C.F.R. Subsection 50.6 of the Code of Federal Regulations of the U.S. Department of Justice. The new PRT programs are scheduled to begin January 1998.

The PRT is a consortium of pharmaceutical companies that provides funds to the AHA for basic biomedical research by independent researchers relating broadly to the causes, prevention and treatment of cardiovascular diseases, including stroke. PRT members provide information about cardiovascular research awareness and collaborate on programs that reach the healthcare professional and consumer audiences. The AHA has decided to make certain changes in the PRT because of changes in the pharmaceutical industry and the changing needs of the AHA.

**Chairman of the Board**  
Marilyn Hunn

**President**  
Martha N. Hill, R.N., Ph.D.

**Chairman-Elect**  
Edward F. Hines, Jr., Esq.

**President-Elect**  
Valentin Fuster, M.D., Ph.D.

**Immediate Past Chairman of the Board**  
David A. Ness

**Immediate Past President**  
Jan L. Breslow, M.D.

**Secretary**  
Henry Morris, Jr., Esq.

**Treasurer**  
Mack S. Linebaugh, Jr.

**Vice Presidents**  
Hugh D. Allen, M.D.  
C. William Balke, M.D.  
William R.H. Broome, Esq.  
Joy S. Frank, Ph.D.  
Donald W. LaVan, M.D.  
Janet Maxson, B.S.N./FNP/PA-C  
Lorrie Peterson, R.N.  
Lawrence B. Sadwin  
Joan Ware, R.N., M.S.P.H.

**Chairperson, Advocacy Coordinating Committee**  
J. Walter Sinclair, Esq.

**Chairperson, Marketing and Communications Coordinating Committee**  
John W. (Jack) Bates

**Chairperson, Scientific Publishing Committee**  
Elizabeth G. Nabel, M.D.

**Chairperson, Scientific Sessions Program Committee**  
Rose Marie Robertson, M.D.

**Members-At-Large**  
R. Wayne Alexander, M.D., Ph.D.  
Claire M. Bassett  
William J. Bryant, Esq.  
Vincent J. Bufalino, M.D.  
Louis L. Cregler, M.D.  
Charles Dennis, M.D.  
Ann E. McPartlin  
Nancy Houston Miller, R.N.  
J.E. Chávez Paisley  
Lynn A. Smaha, M.D., Ph.D.  
Henry M. Sondheimer, M.D.  
Janet O. South  
Donald A. Trimble, C.P.A.  
Jessie G. Wright, M.S., R.D., L.D.

**Executive Vice President**  
Dudley H. Hafner

**Senior Vice President Corporate Operations**  
Walter D. Bristol, Jr.

**Senior Vice President Marketing**  
Jo A. Diehl

**Senior Vice President Communications and Public Advocacy**  
Brigid McHugh Sanner

**Senior Vice President Science and Medicine**  
Rodman D. Starke, M.D.

**Senior Vice President Field Operations**  
M. Cass Wheeler

**Vice President, Corporate Secretary and Counsel**  
David Wm. Livingston, Esq.

Mr. Joel I. Klein  
Page 2  
September 24, 1997

The original seven founding members of PRT were Ciba-Geigy, Bristol-Myers, Sandoz, Squibb, Winthrop Pharmaceuticals, Wyeth-Ayerst and Genentech, Inc. Boehringer-Ingelheim was a regular member. The current members of the PRT are Astra Merck Inc., Bristol-Myers Squibb, Genentech, Inc., Parke-Davis, Pfizer, Inc., Sanofi Pharmaceuticals, Inc. and Wyeth-Ayerst Laboratories.

The proposed changes to the PRT involved are described below:


1. The amount each member will contribute to the PRT will be increased from \$200,000 or \$300,000 annually over a five year period (totaling \$1,000,000 or \$1,500,000) to \$1,000,000 annually for a three year commitment, totaling \$3,000,000.
2. All money has heretofore been used to fund research approved by the AHA. With the proposed changes, sixty percent (60%) of the contributed funds will be used as follows: half for targeted research and half for the funding of AHA approved research grants. The targeted research programs include areas of behavioral science, epidemiology and health services as they relate to the management of risk factors for primary and secondary prevention of cardiovascular disease and stroke. These target research programs will have a peer review process separate from the system of reviewing AHA research applications. Peer reviewers will be recruited from the body of experts from prominent institutions who have experience in the targeted science-based subject areas. The remaining forty percent (40%) of contributed money will fund educational programs. All money will continue to be carefully controlled and budgeted by AHA. Research grant applications will continue to be closely examined by impartial peer review committees whose members are experts in medical and scientific fields.
3. The existing PRT logo will be revised, with either a stacked or side-by-side layout. A copy of the proposed new PRT logo with both layouts along with the proposed revised Graphic Guidelines for Consumer Brands and Pharmaceutical Companies is attached for your reference. PRT members may use the logo in corporate promotional (not product) advertising.

Other than the proposed changes set forth above, the purpose and structure of the PRT as set forth in the 1988 business review request and your response of April 28, 1989 remain the same.

Mr. Joel I. Klein  
Page 3  
September 24, 1997

The documents listed at the close of this letter or referred to herein are included for your reference with regard to this business review request. Should additional information or documents be required in order for a response to be made to this request, please do not hesitate to contact me.

With regards,

A handwritten signature in black ink, appearing to read "David Livingston", with a large, sweeping flourish extending to the right.

David Wm. Livingston  
Vice President, Corporate Secretary & Counsel

Enclosures: Copy of February 1, 1988 Business Review Letter  
Copy of April 28, 1989 Department of Justice Response Letter  
Copy of May 3, 1989 Release of Department of Justice  
Proposed new PRT logo  
Proposed Graphic Standards for proposed new PRT logo